Early access program for Molecular Dynamics' microarray technology gaining momentum.
This article was originally published in The Gray Sheet
Executive Summary
MOLECULAR DYNAMICS DEVELOPING TOXARRAY PRE-ARRAYED DNA TOXICOLOGY SLIDES in collaboration with Phase-I Molecular Technology, company President and CEO Jay Flatley reported at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco. "With Phase-I, we will jointly be developing a series of pre-arrayed DNA slides called ToxArray, using their toxicology technology and then supplying that out to the pharmaceutical partners in our technology access group," Flatley said.